Providence Hematology Logo
Call us: 604 684 5794 ex 4

Publications

Leitch, Heather:

Publications

Leitch HA.  Hematologic Improvement with Iron Chelation Therapy in Acquired Anemias. Eur J Haematol 2016 Jun;96(6):551-2. doi: 10.1111/ejh.12703. No abstract available. PMID: 26572777.

Williamson BT, Foltz L, Leitch HA.  Autoimmune Syndromes Presenting as a Paraneoplastic   Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.  Hematol Rep. 2016 May 10;8(2):6480. doi: 10.4081/hr.2016.6480.  PMID: 27499837.

Alzahrani MF, Radwi M, Leitch HA.  Practical Management of Castleman’s Disease.  Acta Haematol. 2016;136(1):16-22. doi: 10.1159/000444515.  PMID: 27160307.

Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM.  Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.  Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033.  PMID: 26991631.

Tsang E, Leitch HA.  Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving Azacitidine.  Leuk Lymphoma. 2016 Nov;57(11):2709-11. doi: 10.3109/10428194.2016.1157878. No abstract available. PMID: 26980175.

Williamson BT, Leitch HA.  Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.  Case Rep Hematol. 2016;2016:8502641. doi: 10.1155/2016/8502641. PMID: 26904323.

Alzahrani MF, Radwi M, Leitch HA.  Practical Management of Castleman’s Disease.  Acta Haematol. 2016;136(1):16-22. doi: 10.1159/000444515. PMID: 27160307

Leitch HA, Fibach E, Rachmilewitz E.  Toxicity of Iron Overload and Iron Overload Reduction in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.  Crit Rev Onc/Hematol 2016.  Submitted.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating M-M, Sabloff M, St. Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.  Improved Survival in Lower Risk MDS Patients Receiving Iron Chelation Therapy Measured from Time of Red Blood Cell Transfusion Dependence, Adjusting for both MDS and Patient-Related Characteristics: an MDS-CAN Analysis.  Haematologica 2016.  Submitted.

Kochhar H, Leger CS, and Leitch HA.  “Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation”.  Case Reports in Hematology, 2015 accepted for publication.

Tsang E, Leitch HA.  “Pre and Post-Treatment Serum Ferritin Levels in Patients with Lower Risk Myelodysplastic Syndromes Receiving Erythropoiesis Stimulating Agents”.  Leukemia Research, submitted.

Leitch HA. “HIV-Associated Primary Effusion Lymphoma”. In: HIV-Associated Lymphoproliferative Disorders, Barta S and Hentrich M, Eds, Springer Press 2015, sumbitted.

Leitch HA, Thachil J. “Iron metabolism, iron overload, and the porphyrias”.  In: America Society of Hematology Self-Assessment Program Book, A. Cuker, J. DiPaola, and D. Steensma, Eds, 2015, submitted.

Leitch H. Iron cheltion therapy in MDS: does it improve survival? Leuk. Res. 2010; 34(7):852-3.

Leitch H. Delineating parameters of iron overload in MDS patients treated with deferasirox. Leuk. Res. 2010; in press.

Leitch H. Controversies surrounding iron chelation therapy for MDS. Blood Reviews 2010; submitted.

Leitch H. Recent developments toward optimizing iron chelation therapy for MDS. Drugs 2010; in preparation.

Cheung MC, Hicks LK & Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitorbased antiretroviral therapy in the treatment of AIDS-related Hodgkin Lymphoma. Clinical Lymphoma & Myeloma 2010 Apr 1, 10(2):E22-5..

Badawi M, Vickars LM, Chase JM & Leitch HA. Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome: A Case Report and Review of the Literature. Advances in Hematology 2010 28(1):40-8. 164045.

Leitch HA & Vickars LM. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology American Society of Hematology Education Program 2009: 662-70. Review.

Lester R, Li CH, Phillips P, Shenkier TN, Gascoyne RD, Galbraith PF, Vickars LM & Leitch HA. Improved Outcome of Human Immunodeficiency Virus-Associated-Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases: Leukemia & Lymphoma 45(9): 1881-1885, 2004.

Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S & Naiman SC. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. European Journal of Haematology. 2003 Nov;71(5):396-8. Erratum in: European Journal of Haematology. 2004 Apr;72(4):306.

Grants

Kizhakkedathu JN, Leitch H, Scott MD.  Polymer-based bioengineering approaches for systemic iron removal.  CIHR 2013-2018; $615,000.00

Buckstein R, Geddes M, Hasegawa W, Kumar R, Leber B, Leitch H, Sabloff M, Shamy A, Wells R.  MDS Quality of Life in Canada; a national prospective study of the epidemiology, quality of life and impact of comorbidity/frailty on disease outcome. St. Paul’s Hospital Foundation 2013-2018; $103,375.00

Kizhakkedathu JN, Leitch H, Scott MD.  “Polymer-based bioengineering approaches for systemic iron removal”.  CIHR 2013-2018; $615,000.00

Buckstein R, Geddes M, Hasegawa W, Kumar R, Leber B, Leitch H, Sabloff M, Shamy A, Wells R.  “MDS Quality of Life in Canada; a national prospective study of the epidemiology, quality of life and impact of comorbidity/frailty on disease outcome”. St. Paul’s Hospital Foundation 2013-2018; $103,375.00

Book Chapters

Leitch HA. HIV-Associated Primary Effusion Lymphoma. In: HIV-Associated Lymphoproliferative Disorders, Barta S and Hentrich M, Eds, Springer International Publishing 2016.  ISBN 978-3-319-26857-2, DOI 10.1007/978-3-319-26857-6.

Leitch HA, Thachil J. Iron metabolism, iron overload, and the porphyrias.  In: America Society of Hematology Self-Assessment Program Book, A. Cuker, J. DiPaola, and D. Steensma, Eds, 2016.  http://www.ash-sap.org/content/current

Other

Wells RA, Leitch HA, Olney HA, Shamy A.  “MDS ClearPath: a Web-Based Algorithm for the Management of MDS”.  www.mdsclearpath.org; also available for download from the iTunes store.

 

Foltz, Lynda:

Refereed Publications

(a) Journals

Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O’Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335.

Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016 Dec;101(12):e482-e484

Williamson BT, Foltz L, Leitch HA. Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome. Hematol Rep. 2016 May 10;8(2):6480.

Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73.

Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016 Oct;57(10):2464-7.

Bestawros A, Foltz L, Srour N, Savage KJ, Connors JM. Patients’ and physicians’ roles in detecting recurrent Hodgkin lymphoma following complete remission. Ann Oncol. 2012 Dec 9.

Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res. 2012 Nov;36(11):1380-6.

Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA. Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era. Adv Hematol. 2012;2012:910954.

Peterson EA, Zypchen L, Lee VH, Foltz LM. Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. Am J Hematol 2011: 86(9):792-4.

Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40-8.

Foltz L, Song K, Connors J. Hodgkin’s lymphoma in adolescents. J Clin Oncol 2006; 24(16): 2520-2526.

Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsburger C. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 81: 210-211, 2006.

Duncan (Foltz) L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease with serum creatinine: who are we missing? Nephrol Dial Transplant 2001; 16: 1042-1046.

Levin A, Duncan (Foltz) L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, Dumas R, Ross S. A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 2000; 53: 140-146.

Sirrs S, Duncan (Foltz) L, Djurdjev O, Nussbaumer G, Ganz G, Frohlich J and Levin A. Homocysteine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant 1999; 14: 738-743.

Non-Refereed Publications

(a) Journals

Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group. Am J Clin Pathol. 2016 Oct;146(4):408-22.

Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):715-27.

Gupta V, Foltz L, Sirhan S, Busque L, Turner AR. Emerging therapeutic options for myelofibrosis: a Canadian perspective. Am J Blood Res. 2012;2(3):170-86.

Lin Y and Foltz L. Proposed guidelines for platelet transfusion. BC Med J 2005; 47(5): 245-248.

(b) Conference Proceedings

Abstracts

Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, Haifa Kathrin Al-Ali, Anna Marina Liberati, Philipp D. Le Coutre, Alessandro M. Vannucchi, Carmen Garcia-Hernandez, Renato Tavares, Martin Griesshammer, Vikas Gupta, Pia Raanani, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, Sadhvi Khanna, Andrey Zaritskey. Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233) Blood 2016 128:3107; American Society of Hematology Meeting Poster 2016.

Claire Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa. The Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Quality of Life and Productivity: Results from the International MPN Landmark Survey. Blood 2016 128:4267; American Society of Hematology Poster 2016

Haifa Kathrin Al-Ali, Renato Tavares, Giuseppe A. Palumbo, Francesca Palandri, Bruno Martino, Anna Marina Liberati,Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo,Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi and Philipp Le Coutre. Safety and Efficacy of Ruxolitinib in Expanded-Access JUMP Study: An Update From a Cohort of 1869 Patients. Deutsche Gesellschaft für Hämatologie und Onkologie Oral presentation 2016.

Francesco Passamonti, Andrey Zaritskey, Pilar Giraldo, Anna Marina Liberati, Dietger Niederwieser, Francesca Palandri, Pia Raanani,Martin Griesshammer,Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, Vikas Gupta, Bruno Martino, Lynda Foltz, Julian Perez Ronco, Jagannath Ghosh, Catherine Bouard, Renato Tavares. Safety and Efficacy of Ruxolitinib in Patients with DIPSS Intermediate-1 Rish Myelofibrosis from JUMP: An Open-Label, Multicenter, Single-arm Expanded Access Study. European Hematology Association Meeting Poster 2016.

Renato Tavares, Giuseppe A. Palumbo, Philipp Le Coutre, Francesca Palandri, Haifa Kathrin Al-Ali, Bruno Martino, Anna Marina Liberati, Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh,Bayane Tannir, Julian Perez Ronco, and Alessandro M. Vannucchi MD.

Safety and Efficacy of Ruxolitinib in Expanded-Access JUMP Study: An Update From a Cohort of 1869 Patients; European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.

Srdan Verstovsek, Ruben A. Mesa, Lynda M Foltz, Vikas Gupta, John O. Mascarenhas, Ellen K. Ritchie, Ronald Hoffman, Richard Silver, Marina Kremyanskaya, Olga Pozdnyakova, Robert P. Hasserjian, Elizabeth Trehu, Mohamed E Salama, Hagop M Kantarjian, Jason Gotlib. PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. Blood 2015 126:56; American Society of Hematology Meeting Oral Presentation 2015.

Vikas Gupta, Claire N. Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, Wei Peng, Prashanth Gopalakrishna, Hagop Kantarjian, Srdan Verstovsek. The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies. Blood 2015 126:1604. American Society of Hematology Meeting Oral Presentation 2015.

Renato Tavares, Giuseppe A. Palumbo, Philipp Le Coutre, Francesca Palandri, Haifa KathrinAl-Ali, Bruno Martino, Anna Marina Liberati, Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi. Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. Blood 2015 126:2799; American Society of Hematology Meeting Poster Presentation 2015.

Verstovsek S, Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta B, Mascarenhas J, Ritchie E, Hoffman R, Silver R, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J. Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151. Society Hematologic Oncology, Poster Presentation 2015.

Olga Pozdnyakova,Robert Hasserjian, Mohamed Salama, Ruben Mesa, Lynda Foltz, Vikas Gupta, John Mascarenhas, Ellen Ritchie, Ronald Hoffman, Richard Silver, Marina Kremyanskaya, Elizabeth Trehu, Hagop Kantarjian, Jason Gotlib, Srdan Verstovsek. Bone marrow reticulin fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and is associated with normalization of megakaryocyte morphology and improved platelet counts. European Hematology Association Meeting Poster Presentation 2015.

Pilar Giraldo, Francesca Palandri, Giuseppe A. Palumbo, Andrey Zaritskey, Aleksander Skotnicki, Timothy Devos, Domingo Saavedra, Martin Griesshammer, Haifa Kathrin Al-Ali Renato Tavares, Alessandro M. Vannucchi, Vikas Gupta, Pia Raanani, Bayane Tannir, Jagannath Ghosh, Julian Perez Ronco, Lynda Foltz. Safety and Efficacy of Ruxolitinib in Patient with Intermediate-1 Risk Myelofibrosis from an Open-Label, Multicenter, Single-arm Expanded Access Study. European Hematology Association Meeting Poster Presentation 2015.

Pilar Giraldo, Francesca Palandri, Giuseppe A. Palumbo, Andrey Zaritskey, Aleksander Skotnicki, Timothy Devos, Domingo Saavedra, Martin Griesshammer, Haifa Kathrin Al-Ali Renato Tavares, Alessandro M. Vannucchi, Vikas Gupta, Pia Raanani, Bayane Tannir, Jagannath Ghosh, Julian Perez Ronco, Lynda Foltz. Safety and Efficacy of Ruxolitinib in Patient with Intermediate-1 Risk Myelofibrosis from an Open-Label, Multicenter, Single-arm Expanded Access Study. European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.

Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez-Ronco, Lynda Foltz. Effects of Ruxolitinib Treatment on the Prognostic Impact of Anemia in Patients with Myelofibrosis. European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.

Al-Ali H, Le Coutre P, Schlag R, Griesshammer M, Tavares R, Martin B, Vannucchi A, Castellano P, Foltz L, Raanani P, Tannir B, Ghosh J, Perez Ronco J, Gupta V. The Safety and Efficacy of Ruxolitinib in an Open-Label Phase 3B Expanded-Access Study in Myelofibrosis Patients. European School of Hematology Meeting Poster, 2014.

Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez Ronco and Lynda M Foltz, Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF) Blood 2014 124:4583; American Society of Hematology Meeting Poster Presentation 2014.

Srdan Verstovsek, Ruben A. Mesa, Lynda M Foltz, Vikas Gupta, John O Mascarenhas, Ellen K. Ritchie, Ronald Hoffman, Richard T. Silver, Marina Kremyanskaya, Olga Pozdnyakova, Robert P Hasserjian, MD11, Elizabeth Trehu, Hagop M. Kantarjian and Jason R. Gotlib. Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Blood 2014 124:713; American Society of Hematology Meeting Oral Presentation 2014.

Griesshammer M, Vannucchi A, le Coutre P, Tavares R, Al-Ali H, Raanani P, Gupta V, Foltz L, Giraldo P, Bouard C, Perez Ronco J, Ghosh J, Martino B. Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF). Blood 2014 124:1859; American Society of Hematology Meeting Poster Presentation 2014.

Mascarenhas J,Talpaz M, Gupta V, Foltz L, Savona M, Paquette R, Turner R, Paul Coughlin, Elliott Winton, MD, Deborah Hunter, Albert Assad, Jason Clark, Peter O’Neill, Ronald Hoffman, Srdan Verstovsek. Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis. Blood 2014 124:714; American Society of Hematology Meeting Oral Presentation 2014.

Bruno Martino, Philipp le Coutre, Martin Griesshammer, Thomas Illmer, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, Renato S Tavares, Alessandro M. Vannucchi, MD, Pilar Giraldo, Lynda M Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jaggannath Ghosh and Haifa Kathrin Al-Ali. Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update. Blood 2014 124:3197; American Society of Hematology Meeting Poster Presentation 2014.

Bestawros A, Foltz L, Srour N, Connors J. Patients’ versus physicians’ roles in detecting recurrent Hodgkin lymphoma. J Clin Oncol 2011: 29: 8041.
Poster Presentation American Society of Clinical Oncology, 2011.

Leitch H, Chan C, Leger C, Foltz L, Ramadan K, Vickars L. Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Associated in Patients with a Non-RARS Diagnosis. Blood 2011; 118: 1732.
Poster Presentation, American Society of Hematology Annual Meeting, 2011.

Ambler K, Vickars L, Leger C, Foltz L, Montaner J, Harris M, Leitch H. Clinical Features, Treatment and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura in the HAART Era. Blood, 2010, 116: 2522.
Poster Presentation, American Society of Hematology Annual Meeting, 2010.

Lee V, Peterson E, Zypchen L, Foltz LM. Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice. Blood 2009: 114: 1903.
Poster Presentation, American Society of Hematology Annual Meeting, 2009.

Peterson E, Zypchen L, Nitta J, Berkowitz J, Foltz LM. Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia. Blood 2009: 114:2916. Poster Presentation, American Society of Hematology Annual Meeting, 2009.

MacKenzie-Feder J, Eaves C, Lambie K, Abdi-Ali A, Ramadan K, Young S, Horsman D, Galbraith P, Eaves A, Foltz L. Role of serum erythropoietin, erythropoietin-independent erythroid colony formation and bone marrow assessment in the diagnosis of polycythemia vera in patients with JAK2 V617F mutation. J Clin Oncol 2009, 27: 7085. Poster Presentation American Society of Clinical Oncology, 2009.

Leitch H, Ezzat H, Rollins M, Goodman T, Leger C, Wong D, Ramadan K, Foltz L, Vickars L. Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis Receiving Iron Chelation Therapy. Blood 2008: 112:1748. Poster Presentation, American Society of Hematology Annual Meeting, 2008

Alipour S, Leitch H, Vickars L, Foltz LM, Galbraith P, Leger C, Ramadan K. Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome. Blood 2008: 112:3179.
Poster Presentation, American Society of Hematology Annual Meeting, 2008

Foltz L, Song K, Connors, J. Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician? Blood 2004; 104 (11): 3124. Poster Presentation, American Society of Hematology Annual Meeting, 2004

Foltz L, Galbraith P. Autoimmune Hemolytic Anemia and HIV. Poster presentation, ACP-ASIM Annual Meeting, 2002

Duncan (Foltz) L, Heathcote J, Djurdjev O, Levin A. Screening for Renal Disease with Serum Creatinine: Who are we missing? JASN, 1998; 9: 153A. Poster presentation, American Society of Nephrology Annual Meeting, 1998

Duncan (Foltz) L, Luscombe R, Whitlam L, Nussbaumer G, Werb R, Levin A. Infection and malfunction in temporary and permanent hemodialysis catheters: assessment of similarities and differences. Poster presentation, Canadian Society of Nephrology Annual Meeting, 1998

Levin A, Duncan (Foltz) L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, Ross S. A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Invest Med, 1997; 20(4) supplement; S68.
Oral Presentation, American Society of Nephrology Annual Meeting, 1997.

 

Shannon, Jackson:

Publications

Adult males with hemophilia have a different macrovascular and microvascular endothelial function profile compared with healthy controls. Sun L, Yang M, Fung M, Chan S, Jawi M, Anderson T, Poon M-C; Jackson S. Haemophilia 2017, In press

Switching to Extended Half-life products in Canada – Preliminary data. Keepanasseril A, Stoffman J, Bouskill V, Carcao C, Iorio A, Jackson S, on behalf of the Association of Hemophilia Centre Directors of Canada (AHCDC). Haemophilia 2017, DOI: 10.1111/hae.13245

Prevalence and predictors of loss to follow-up in young adults with mild hemophilia. Sun L, McIntosh K, Woo C, Crilly E, Bartholomew C, Gue D, De Marchi L, Squire S, Silva A, Yang M, Wu J, Jackson S. Haemophilia 2017;23(1): e36–e39

Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era. Recht M, Konkle BA, Jackson S, Neufeld EJ, Rockwood K, Pipe S. Haemophilia 2016; 22 (6): 825–832.

Sun H, Yang M, Sait A, von Drygalski A, Jackson S. Hematuria is Not a Risk Factor of Hypertension or Renal Impairment in Patients with Hemophilia. Haemophilia 2016; 22(4): 549–555

Nolan B, Mahlangu J, Perry D, Young G,  Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi J,  Pabinger I, Jackson S, Cristiano L, Li X, Pierce G, Allen G.  Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016; 22(1): 72-80

Fieldwalker M, Jackson SC & Seal D. High Transoxygenator Pressure Gradient in a Patient With Polycythemia Vera. Journal of Cardiothoracic and Vascular Anesthesia. April 2009. DOI: 10.1053/j.jvca.2009.01.031.

Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML & Poon MC. The Montreal Platelet Syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009;113:3348-3351.

Jackson S, Beck P, Buret A, O’Connor P, Meddings J, Pineo G & Poon MC. Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. International Journal of Hematology. 2008;88 (2): 212-8.

Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Eaves CJ, Jackson S, Poon MC, Sinclair G, Leber B, Johnson PR, Macheta A, Yin JA, Lister TA, Barnett MJ & Fitzgibbon J. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Blood 2008; 112:4639-4645.

Deyell R, Jackson S, Spier S, Le D & Poon MC. Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin Titusville. Journal of Pediatric Hematology Oncology. 28(2):100-2, 2006.

Jackson S, Beck PL, Pineo GF & Poon MC. Helicobacter Pylori Eradication: A Novel Therapy for Immune Thrombocytopenic Purpura? A Review of the Literature. American Journal of Hematology 78(2):142-150; 2005.

Grants

2016, Biogen IIR Research Grant:  Factor product utilization and health outcomes in patients with hemophilia A and B in Canada:  an observational multicenter Canadian study of real-world outcomes, Principal Investigator: $557,000

2016, Canadian Hemophilia Society: Outcomes Indicators of Transitional Care in Adolescents with Hemophilia:A Delphi Survey of Canadian Hemophilia Care Providers and Patient Focus Groups, Co-investigator and supervisor: $40,000.

2015, Baxter IIR Research Grant: Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Canadian Patients with Hemophilia, Co-Principal Investigator, $350,000

 

Other Publications (Most Recent First)

Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Léger CS, Ramadan KM, Barnett MJ & Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematological Oncology 2010;28(1):40-8.

Léger CS, Leitch HA, Galbraith PF, Li CH & Vickars LM. Acute Leukemia in Patients Sixty Years of Age and Older: A Twenty Year Single Institution Review. American Journal of Clinical Oncology 2009 Apr; 32(2):137-41.

Au NH, Wong AY, Vickars L, MacGillivray RT & Wadsworth LD. Two new examples of Hb St. Etienne [beta 92(F8)HisGln] in association with venous thrombosis. Hemoglobin. 2009;33(2):95-100.

Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Betancourt MT & Kovacs MJ. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417-26.

Wells RA, Leber B, Buckstein R, Lipton JH, Hasegawa W, Grewal K, Yee K, Olney HJ, Larratt L, Vickars L & Tinmouth A. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk. Res. 2008 Sep;32(9):1338-53. Epub 2008 Apr 11.

Leitch HA, Léger CS, Goodman TA, Wong KK, Wong DHC, Ramadan KM, Rollins MD, Barnett MJ, Galbraith PF & Vickars LM. Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy. Clinical Leukemia 2008; 2(3):205-211. Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, LeBlanc R, Belch AR, White D & Kovacs MJ. Treatment of relapsed and refractory myeloma. Leukemia & Lymphoma 2008; 49(8):1470–1485.

Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA & Toze CL. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplantation. 2008 Nov; 42(9):601-8.

El-Agnaf M, McCoy C, Ong Y-L, Eswedi A H, Black B & Ramadan K. Infusion of Rituximab Over 90-minutes on an Out-Patient Basis is Safe and Improves Resource Utilization. Leukemia and Lymphoma, Volume 48, Issue 9, Pages: 1875-1877. September 2007.

Ramadan K, Shenkier T, Sehn L, Gascoyne R & Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Annals of Oncology, Volume 18, Issue 1, Pages 129-135, January 2007.

Fung SS, Hillier KL, Leger CS, Sandhu I, Vickars LM, Galbraith PF, Li CH & Leitch HA. Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis. Leuk Lymphoma. 2007 Jun;48(6):1087-91.

Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K & Meyer RM. A randomized comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 2007 Jan;136(2):203-211.

Ramadan K, McKenna K & Morris TCM. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. The Lancet Oncology, Volume 7, Issue 11, Pages: 958-959, November 2006.

Ramadan K, McNulty O, Anderson J, Jones F & Winter P. A novel factor XI gene mutation associated with mild factor XI deficiency in a symptomatic patient. Blood Coagulation and Fibrinolysis Journal, Volume 17, Issue 6, Page 499-502, Sep 2006.

Ramadan K, Kyle A, McManus D, O’Rourk D & Cuthbert RGJ. Urinary bladder infiltration with chronic Blymphocytic leukaemia: Two cases with unusual presentation. Leukemia and Lymphoma. Volume 47, Issue 6, Page: 1184-1187. June 2006.

Knott M, Ramadan K, Savage G, Jones FGC, El-Agnaf M, McMullin MF & Percy MJ. Novel and Mediterranean beta thalassaemia mutations in the indigenous Northern Ireland population. Blood Cells, Molecules and Diseases. Volume 36, Issue 2, Page: 265-268. April 2006.

Laneuville P, Barnett MJ, Belanger R, Couban S, Forrest DL, Roy DC & Lipton JH. Recommendations of the Canadian Consensus Group on the management of chronic myeloid leukemia. Current Oncology 13: 1- 20, 2006.

Léger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C, Zhang H & Huebsch L. Outpatient Autologous Hematopoietic Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma. Annals of Hematology 85; 10: 723-729, October 2006.

Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K & Kollmannsburger C. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. American Journal of Hematology 81: 210-211, 2006.

Lin Y & Foltz L. Proposed guidelines for platelet transfusion. BC Medical Journal 2005; 47(5): 245-248.

Ramadan K & Cahill M. Successful intra-articular chemotherapy for relapsed acute myeloid leukemia infiltrating the knee joint, a case report. British Journal of Hematology, Volume 124, No. 3, PP 258, February-I 2004.

Bredeson C, Léger C, Couban S, Simpson D, Huebsch L, Walker I, Shore T, Howson-Jan K, Panzarella T, Messner H, Barnett M & Lipton J. An evaluation of the donor experience in the Canadian Multicenter randomized trial of bone marrow versus peripheral blood allografting. Biology of Blood and Marrow Transplantation 10: 405-414, 2004.

Léger CS & Nevill T. Hematopoietic stem cell transplantation: A primer for the primary care physician, Review article. Canadian Medical Association Journal 170: 1569-1577, 2004.

Diaz-Mitoma F, Léger CS, Miller H, Giulivi A, Frost R, Shaw L & Huebsch L. Comparison of DNA amplification, mRNA amplification, and DNA hybridization techniques for detection of cytomegalovirus in bone marrow transplant recipients. Journal of Clinical Microbiology 41(11): 5159-5166, 2003.

Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, Amess JAL, Rohatiner AZS, Lister TA & Barnett MJ. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reducedintensity allografting. Journal of Clinical Oncology 21: 3060 – 3065, 2003.

Gill S, Naiman SC, Jamal A & Vickars LM. Massive bleeding on a bladder protectant: a case report of pentosan polysulfate sodium-induced coagulopathy. Archives of Internal Medicine 162 (14): 1644-5, 2002.

Couban S, Simpson DR, Barnett MJ, Bredeson C, Huebsch L, Howson-Jan K, Shore TB, Walker IR, Browett P, Messner HA, Panzarella T & Lipton JH. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100: 1525 –1531, 2002.

Léger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous Blood and Marrow Transplantation in Patients 60 Years and Older. Biology of Blood and Marrow Transplantation 6:204-210, 2000.

Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann H-G, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA & Barnett MJ. Cytoegenetic abnormalities in primary meylodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92: 1910-1917, 1998.

Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humphries RK, Klingemann H-G, Lansdorp PM, Nantel SH, Reece DE, Spinelli JJ, Sutherland HJ & Eaves AC. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 84: 724 – 732, 1994.

Chow EY, Haley LP, Vickars L & Murphy MJ. A case of bromadiolone (superwarfarin) ingestions. Canadian Medical Association Journal, Vol. 147 (1), 1992.

Vickars L, Coupland RW & Naiman SC. The response of an acquired Factor V inhibitor to activated Factor IX concentrate. Year book of Anaesthesia, 1986.

Vickars L, Coupland RW & Naiman SC, Acquired factor V inhibitor – A therapeutic response to autoplex transfusion, Vol. 25, 1985.

Other Abstracts (Most Recent First)

Lee VHY, Peterson E, Zypchen L & Foltz LM. Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice. 51st Annual Meeting of the American Society of Hematology, 2009: Abstract 1903.

Peterson E, Zypchen L, Nitta J, Berkowitz J & Foltz LM. Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia. 51st Annual Meeting of the American Society of Hematology, 2009: Abstract 2916.

MacKenzie-Feder JM, Eaves C, Lambie K, Abdi-Ali A, Ramadan KM, Young S, Horsman D, Galbraith P, Eaves A & Foltz L. A high hemoglobin and the presence of JAK2-mutant cells is sufficient to make a diagnosis of polycythemia vera. 2009 ASCO Annual Meeting. American Society of Clinical Oncology, 2009.

Leitch HA, Badawi M, Chase JM & Vickars LM. Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome: A Case Report and Review of the Literature. Haematologica 2009:94(s2):539: Abstract 1369.

Leitch HA, Ezzat H, Rollins MD, Goodman TA, Léger CS, Wong DHC, Ramadan KM, Foltz LM & Vickars LM. Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy. Blood 2008; 112(11): Abstract 1748.

Ezzat H, Cheung MC, Hicks LK, Murphy KC, Léger CS, Taggart LR, Boro J, Montaner JSG, Harris M, Vickars LM & Leitch HA. Incidence, Predictors and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma. Blood 2008; 112(11): Abstract 2587.

Alipour S, Leitch HA, Vickars LM, Foltz LM, Galbraith PF, Léger CS & Ramadan KM. Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome. Blood 2008; 112(11): Abstract 3179.

Alipour S, Leitch HA, Vickars LM, Foltz LM, Galbraith PF, Léger CS & Ramadan KM. A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia. Blood 112(11), 2008: Abstract: 4185.

Alipour S, Leitch HA, Vickars LM, Foltz LM, Galbraith PF, Léger CS & Ramadan KM. CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available. Blood 112(11) 2008: Abstract 4190.